Ophthalmic CRO Ora is inheriting a relationship with drugmaker Nicox after the French outfit agreed to buy Aciex Therapeutics, a Boston-based biotech at work on eye treatments.
Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.
Quintiles has wrapped up its acquisition of healthcare analytics provider Encore, part of the CRO's push to grow its post-market services.
Scottish contractor BioOutsource is planning a deeper dive into the U.S. market for development services, setting sights on a new lab in Massachusetts to serve its American clientele.
Contract developer Catalent is planning to open a new facility in Japan as it marks 40 years doing business in the country, looking to expand its scale in R&D and manufacturing.
Parexel International is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.
Contract developer Recipharm and CTC Clinical Trial Consultants are joining forces to offer combined Phase I services, pooling their capabilities in manufacturing and trial conduction.
German contractor Evotec has notched another milestone in its years-long arrangement with Boehringer Ingelheim, netting €1 million ($1.4 million) after moving a respiratory compound into preclinical study.
CRO ClinicalRM has signed a deal with the Ohio Clinical Trials Collaborative to join forces in a co-marketing arrangement, looking to expand its role in the state's drug and device development scene.
Bristol-Myers Squibb has tapped Duke University's in-house CRO to pitch in on clinical trial transparency, asking the organization's researchers to independently review requests for shared data.
Parexel figures it can rake in more than $2 billion in revenue in the next fiscal year, banking on a solid book-to-bill ratio and increasing global demand to deliver an all-time high.
As last week's BIO conference well illustrated, biotech companies go to great lengths to flaunt their assets in front of potential partners from Big Pharma. Global CRO Covance is developing a system it believes can make that process more efficient: an online platform that allows drug developers to securely list their up-for-license molecules for would-be collaborators.
Catalent and Perrigo will be able to sell generic versions of Teva's ProAir HFA inhaler starting in late 2016, resolving a patent dispute between the two parties.
Parexel International has reformatted its clinical trial management software, streamlining its services with an update the company believes can help its clients start studies faster.
Welsh CRO Simbec Research is expanding beyond its focus on early-phase studies, buying up Orion Clinical Services in a move the company says will make it a full-service organization.
Japan's CROèe, a patient-recruitment-focused contractor, has deepened its ties with partner BBK, launching a joint venture in the U.S. to provide a gateway into the country's growing market for drug development.
Quintiles believes in better drug sales through data analytics, signing a deal with a marketing-optimization company to pool resources and figure out how to better reach physicians on behalf of its commercialization clients.
Just three months after wrapping its latest merger, BioClinica has made another acquisition, snapping up Blueprint Clinical to expand its capabilities in the growing field of risk-based management.
A year removed from the $1.3 billion deal that made it a top-5 CRO, PRA has integrated its various acquisitions and is rebranding itself as a sprawling global drug development resourcer.